Table 2. Efficacy endpoints in the intention-to-treat and per-protocol populations.

	Number of events in the intention-to-treat population			Number of events in the per-protocol population
	Aspirin (n=6270)	Placebo (n=6276)	Hazard ratio (95% CI); p value	Aspirin (n=3790)	Placebo (n=3912)	Hazard ratio (95% CI); p value
Myocardial infarction, stroke, cardiovascular death, unstable angina, or transient ischaemic attack	269 (4·29%)	281 (4·48%)	0·96 (0·81–1·13); p=0·6038	129 (3·40%)	164 (4·19%)	0·81 (0·64–1·02); p=0·0756
Myocardial infarction, stroke, or cardiovascular death	208 (3·32%)	218 (3·47%)	0·95 (0·79–1·15); p=0·6190	103 (2·72%)	135 (3·45%)	0·79 (0·61–1·02); p=0·0661
Myocardial infarction*	95 (1·52%)	112 (1·78%)	0·85 (0·64–1·11); p=0·2325	37(0·98%)	72 (1·84%)	0·53 (0·36–0·79); p=0·0014
Non-fatal myocardial infarction	88 (1·40%)	98 (1·56%)	0·90 (0·67–1·20); p=0·4562	32 (0·84%)	60 (1·53%)	0·55 (0·36–0·84); p=0·0056
Stroke*	75 (1·20%)	67 (1·07%)	1·12 (0·80–1·55); p=0·5072	40 (1·06%)	37 (0·95%)	1·12 (0·71–1·75); p=0·6291
Cardiovascular death	38 (0·61%)	39 (0·62%)	0·97 (0·62–1·52); p=0·9010	26 (0·69%)	26 (0·66%)	1·03 (0·60–1·77); p=0·9161
Unstable angina	20 (0·32%)	20 (0·32%)	1·00 (0·54–1·86); p=0·9979	8 (0·21%)	11 (0·28%)	0·75 (0·30–1·87); p=0·5380
Transient ischaemic attack	42 (0·67%)	45 (0·72%)	0·93 (0·61–1·42); p=0·7455	19 (0·50%)	19 (0·49%)	1·03 (0·55–1·95); p=0·9181
Any death	160 (2·55%)	161 (2·57%)	0·99 (0·80–1·24); p=0·9459	108 (2·85%)	101 (2·58%)	1·10 (0·84–1·45); p=0·4796

^*Fatal or non-fatal.